AGTC Applied Genetic Technologies Corporation

3.25
-0.22  -6%
Previous Close 3.47
Open 3.44
Price To Book 0.75
Market Cap 58935477
Shares 18,133,993
Volume 340,524
Short Ratio
Av. Daily Volume 140,884

SEC filingsSee all SEC filings

  1. 8-K - Current report 181232226
  2. 8-K - Current report 181192960
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173449
  4. 8-K - Current report 181168160
  5. DEF 14A - Other definitive proxy statements 181124752

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dose escalation part of trial to be completed 1Q 2019.
AAV Gene Therapy
CNGB3 Achromatopsia
Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
rAAV-hRS1
X-linked retinoschisis (XLRS)
Phase 1/2 dose escalation part of trial to be completed 1Q 2019.
AAV-based gene therapy
X-linked Retinitis Pigmentosa (XLRP)

Latest News

  1. Applied Genetic Technologies Enters Oversold Territory
  2. Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
  3. The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
  4. Today's Research Reports on Trending Tickers: Novavax and Applied Genetic Technologies
  5. Edited Transcript of AGTC earnings conference call or presentation 8-Nov-18 1:00pm GMT
  6. AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
  7. Applied Genetic Technologies (AGTC) Tops Q1 Earnings and Revenue Estimates
  8. Applied Genetic Technologies: Fiscal 1Q Earnings Snapshot
  9. AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2018
  10. AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 8, 2018
  11. Earnings Preview: Applied Genetic Technologies (AGTC) Q1 Earnings Expected to Decline
  12. Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update
  13. Edited Transcript of AGTC earnings conference call or presentation 10-Sep-18 8:30pm GMT
  14. Applied Genetic Technologies Corp (AGTC) Files 10-K for the Fiscal Year Ended on June 30, 2018
  15. Earnings Outlook for Applied Genetic Tech

SEC Filings

  1. 8-K - Current report 181232226
  2. 8-K - Current report 181192960
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173449
  4. 8-K - Current report 181168160
  5. DEF 14A - Other definitive proxy statements 181124752
  6. 8-K - Current report 181084198
  7. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 181063810
  8. 8-K - Current report 181062805
  9. 8-K/A [Amend] - Current report 18985972
  10. 8-K - Current report 18981470